mRNA Cap-2'-O-Methyltransferase
| Catalog No. | ON-014 |
| Purity | ＞95% by SDS-PAGE |
| Storage Condition | -20℃ |
| Source | Recombinant E.coli |
mRNA Cap-2'-O-Methyltransferase
mRNA Cap-2'-O-Methyltransferase - M (Molecular Biology) / Non-GMP / 5kU / centrifuge tube is backordered and will ship as soon as it is back in stock.
Couldn't load pickup availability
Shipping notes
Shipping notes
Related Products
-
Catalog No.: ON-028
Purity: ＞95% by SDS-PAGE
Source: Recombinant E.coli
From$145.00 -
-
Details
Details
Product Information
mRNA Cap-2'-O-Methyltransferase is a recombinant protein from Vaccinia virus. The enzyme can add a methyl group at the 2'-O position of the first nucleotide adjacent to the Cap structure at the 5' end of the RNA. The enzyme utilizes SAM as a methyl donor to methylate capped RNA (Cap 0) resulting in a cap-1 structure. The Cap-1 structure has been reported to enhance mRNA translation efficiency and hence may help improve expression in mRNA transfection and microinjection experiments. mRNA cap-2'-O-Methyltransferase specifically requires RNA with an m7GpppN Cap as substrate.
Source: Recombinant E.coli
Concentration: 50U/μL
Unit Definition: One unit is defined as the amount of enzyme required to methylate 10pmols of 80 nt Capped RNA transcript in 1 hour at 37℃.
Storage Buffer: 20mM Tris-HCl (pH8.0), 0.1mM EDTA, 100mM NaCl, 1mM DTT, 0.1%(v/v) Triton X-100, 50%(v/v) glycerol.
Companion Products:
- 50mM KCl
- 10mM MgCl2
- 10mM DTT;
Key points of operation
- Do not resuspend the RNA in an EDTA-containing solution.
- To enhance the stability of RNA in solution, RNase inhibitor is desired, which can be add to a final concertation of 1U/ul at the time of reaction set-up.
- SAM is unstable at pH 7-8, 37℃ and should be mixed fresh for each reaction series. We recommend determining how many reactions will be performed and diluting an aliquot of the 32mM stock to 2mM.
- Heating the solution of RNA prior to incubation with Vaccinia capping enzyme, to remove secondary structure on the 5' end of the transcripts. For highly structured 5' ends, increase the RNA heat-denaturation conditions used. For example, 65℃ for 20 min, 75℃ for 10 min, 85℃ for 5 min, etc…
- Vaccinia Capping Enzyme and 2'-O-methyltransferase work together to produce the Cap 1 structure.
- Capping reaction incubation time can be Increased up to 3 hours at 37℃ for a high capping efficiency for transcripts with known structured 5' ends.
Security Information
Storage Conditions: -20℃
Quality Assurance: Free of Endonuclease, Exonuclease, and RNase activities.
Physical Purity: ＞95% by SDS-PAGE.
Reference
1. THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 250, No. 24, Issue of December 25, pp. 9322-9329,1975.
2. Kuge, H. et al., (1998) Nucl. Acids Res. 26, 3208.
Specifications
Specifications
-
Catalog No.ON-014ON-014-G
-
SourceRecombinant E.coliRecombinant E.coli
-
Purity＞95% by SDS-PAGE＞95% by SDS-PAGE
-
Storage Condition-20℃-20℃
Documentation
Documentation
Product Information
mRNA Cap-2'-O-Methyltransferase is a recombinant protein from Vaccinia virus. The enzyme can add a methyl group at the 2'-O position of the first nucleotide adjacent to the Cap structure at the 5' end of the RNA. The enzyme utilizes SAM as a methyl donor to methylate capped RNA (Cap 0) resulting in a cap-1 structure. The Cap-1 structure has been reported to enhance mRNA translation efficiency and hence may help improve expression in mRNA transfection and microinjection experiments. mRNA cap-2'-O-Methyltransferase specifically requires RNA with an m7GpppN Cap as substrate.
Source: Recombinant E.coli
Concentration: 50U/μL
Unit Definition: One unit is defined as the amount of enzyme required to methylate 10pmols of 80 nt Capped RNA transcript in 1 hour at 37℃.
Storage Buffer: 20mM Tris-HCl (pH8.0), 0.1mM EDTA, 100mM NaCl, 1mM DTT, 0.1%(v/v) Triton X-100, 50%(v/v) glycerol.
Companion Products:
- 50mM KCl
- 10mM MgCl2
- 10mM DTT;
Key points of operation
- Do not resuspend the RNA in an EDTA-containing solution.
- To enhance the stability of RNA in solution, RNase inhibitor is desired, which can be add to a final concertation of 1U/ul at the time of reaction set-up.
- SAM is unstable at pH 7-8, 37℃ and should be mixed fresh for each reaction series. We recommend determining how many reactions will be performed and diluting an aliquot of the 32mM stock to 2mM.
- Heating the solution of RNA prior to incubation with Vaccinia capping enzyme, to remove secondary structure on the 5' end of the transcripts. For highly structured 5' ends, increase the RNA heat-denaturation conditions used. For example, 65℃ for 20 min, 75℃ for 10 min, 85℃ for 5 min, etc…
- Vaccinia Capping Enzyme and 2'-O-methyltransferase work together to produce the Cap 1 structure.
- Capping reaction incubation time can be Increased up to 3 hours at 37℃ for a high capping efficiency for transcripts with known structured 5' ends.
Security Information
Storage Conditions: -20℃
Quality Assurance: Free of Endonuclease, Exonuclease, and RNase activities.
Physical Purity: ＞95% by SDS-PAGE.
Reference
1. THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 250, No. 24, Issue of December 25, pp. 9322-9329,1975.
2. Kuge, H. et al., (1998) Nucl. Acids Res. 26, 3208.
-
Catalog No.ON-014ON-014-G
-
SourceRecombinant E.coliRecombinant E.coli
-
Purity＞95% by SDS-PAGE＞95% by SDS-PAGE
-
Storage Condition-20℃-20℃
Why choose Hongene?
Trusted Partner in Nucleic Acid
Enjoy enterprise‑grade quality even with small batch orders.
Integrated Supply & Commercial Scale
With nearly 30 years of expertise, we control a secure supply chain for RNA raw materials and provide reliable GMP-grade oligo synthesis from research to commercial kilogram-scale production.
Proprietary Technology & IP
Our proprietary Chemoenzymatic Ligation Platform combines chemical andenzymatic methods, enabling high-putity, cost-effective, and large-scale production of RNA-based therapeutics.
Rigorous Quality
We implement multiple stringent QC steps, maintain ISO certifications, and ensure >99% batch-to-batch consistency, reducing scale-up and PPQ risks.
Manufacturing Scalability
Hongene operates a 1.67-million-square-foot oligonucleotide manufacturing facility featuring advanced equipment, including multiple OligoPilot™ and OligoProcess™ synthesizers ranging from 10 to 1,800 mmol. Its 48 flexible production lines enable seamless, one-stop scale-up of API production from gram-level quantities to metric tons, achieving purity of ≥98% while supporting compliance with NMPA, FDA, and EMA regulatory requirements.
Global Business Network
Our products and services reach over 40 countries and regions, supporting around 3,000 clients worldwide.
